We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer

News   Apr 07, 2011

 
OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
 
 
Advertisement
 

RELATED ARTICLES

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

Circulating DNA From Tumor Could Predict Immunotherapy Outcome

News

A newly developed test that detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, according to researchers.

READ MORE

mRNA-1273 COVID-19 Vaccine Protects Airway in Nonhuman Primate Study

News

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE